We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arix Bioscience Plc | LSE:ARIX | London | Ordinary Share | GB00BD045071 | ORD 0.001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 142.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
Arix Bioscience plc
Notice of Annual General Meeting
Announcement of format of 2020 Annual General Meeting
LONDON, 12 May 2020: Arix Bioscience plc (“Arix” or the ”Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that its Annual General Meeting (“AGM”) will be held at the Company's offices at 20 Berkeley Square, London, W1J 6EQ from 2:00pm on Thursday 4 June 2020.
Notice of the AGM and the Form of Proxy were posted to shareholders on 7 May 2020. In compliance with Listing Rule 9.6.1, these documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.
In accordance with UK Government instructions issued on 23 March 2020, it is regretted that shareholders must not attend the AGM in person but are encouraged to submit their vote by proxy by 2.00pm BST on Tuesday 2 June 2020. Details of the procedure for doing so are set out in the Notice of Meeting which has been posted to shareholders and is available on the Company’s website.
The Directors believe that the resolutions to be put to the meeting are in the best interests of the Company and its shareholders as a whole, and unanimously recommend that that shareholders vote in favour of all proposed resolutions.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Robert Lyne, Company Secretary
+44 (0)20 7290 1055
robert@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Shabnam Bashir
+44 (0)20 3950 9144
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
www.arixbioscience.com
Copyright y 12 PR Newswire
1 Year Arix Bioscience Chart |
1 Month Arix Bioscience Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
